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here is no doubt that dopaminergic, serotoner-
gic, and/or noradrenergic neurotransmission play an
important role in the pathophysiology of major depres-
sion (MD) and schizophrenia. Although the roles of
dopamine in schizophrenia and of serotonin and nora-
drenaline in depression have been studied intensively,
the exact underlying pathological mechanisms of both
disorders are still unclear. 
In MD, glutamatergic hyperfunction seems to be closely
related to the lack of serotonergic and noradrenergic neu-
rotransmission. Altered glutamate levels have been
observed in the plasma, serum, cerebrospinal fluid (CSF),
and in imaging and postmortem studies of depressed
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An inflammatory pathogenesis has been postulated for schizophrenia and major depression (MD). In schizophrenia
and depression, opposing patterns of type-1 vs type-2 immune response seem to be associated with differences in the
activation of the enzyme indoleamine 2,3-dioxygenase and in the tryptophan-kynurenine metabolism, resulting in
increased production of kynurenic acid in schizophrenia and decreased production of kynurenic acid in depression.
These differences are associated with an imbalance in the glutamatergic neurotransmission, which may contribute to
an excessive agonist action of N-methyl-D-aspartate (NMDA) in depression and of NMDA antagonism in schizophre-
nia. Regarding the neuroprotective function of kynurenic acid and the neurotoxic effects of quinolinic acid (QUIN),
different patterns of immune activation may also lead to an imbalance between the neuroprotective and the neuro-
toxic effects of the tryptophan/kynurenine metabolism. The differential activation of microglia cells and astrocytes
may be an additional mechanism contributing to this imbalance. The immunological imbalance results in an inflam-
matory state combined with increased prostaglandin E2 production and increased cyclo-oxygenase-2 (COX-2) expres-
sion. The immunological effects of many existing antipsychotics and antidepressants, however, partly correct the
immune imbalance and the excess production of the neurotoxic QUIN. COX-2 inhibitors have been tested in animal
models of depression and in preliminary clinical trials, pointing to favorable effects in schizophrenia and in MD. 
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1 In schizophrenia, in contrast, dopaminergic
hyperfunction in the limbic system and dopaminergic
hypofunction in the frontal cortex are thought to be the
main neurotransmitter disturbances. Recent research pro-
vides further insight that glutamatergic hypofunction
might be the cause for this dopaminergic dysfunction in
schizophrenia,
2 whereas glutamatergic hyperfunction acts
through low NMDA antagonism in the kynurenine path-
way in MD.
3 Glutamatergic dysfunction seems to be a
common pathway in the neurobiology of schizophrenia
and depression. The glutamatergic system is closely related
in function to the immune system and to the tryptophan-
kynurenine metabolism, which both seem to play a key
role in the pathophysiology of schizophrenia and MD.
4,5
The immune response and type-1 
and type-2 polarization
The innate immune system is phylogenetically the old-
est part of the immune response, natural killer (NK)
cells and monocytes as the first barrier of the immune
system being part of this. The adaptive immune response
with the antibody-producing B-lymphocytes, the T-lym-
phocytes and their regulating “immunotransmitters,” the
cytokines, is the specifically acting component of the
immune system. (Tables I and II). Cytokines regulate all
types and all cellular components of the immune system,
including the innate immune system. Helper T-cells are
of two types, T-helper-1 (TH-1) and T-helper-2 (TH-2).
TH-1 cells produce the characteristic “type-1” activating
cytokines such as interleukin (IL) -2 and interferon
(IFN)-γ. However, since not only TH-1 cells, but also cer-
tain monocytes/macrophages (M1) and other cell types
produce these cytokines, the immune response is called
the type-1 immune response. The humoral, antibody-
producing arm of the adaptive immune system is mainly
activated by the type-2 immune response. TH-2 or cer-
tain monocytes/macrophages (M2) produce mainly IL-
4, IL-10, and IL-13.
6 Further terminology separates the
cytokines into proinflammatory and anti-inflammatory
types. Proinflammatory cytokines, such as tumor necro-
sis factor α (TNF-α) and IL-6 are primarily secreted
from monocytes and macrophages, activating other cel-
lular components of the inflammatory response. While
TNF-α is an ubiquitiously expressed cytokine mainly
activating the type-1 response, IL-6 activates the type-2
response including the antibody production. Anti-
inflammatory cytokines such as IL-4 and IL-10 help to
downregulate the inflammatory immune response.
The type-1 immune system promotes the cell-mediated
immune response directed against intracellular pathogens,
whereas the type-2 response helps B-cell maturation and
promotes the humoral immune response, including the
production of antibodies directed against extracellular
pathogens. Type-1 and type-2 cytokines antagonize each
other in promoting their own type of response, while sup-
pressing the immune response of the other; therefore the
term “polarized” can be used.
Inflammation in schizophrenia 
and depression
Infection during pregnancy in mothers of offspring who
later develop schizophrenia has been repeatedly
described, in particular in the second trimester.
7,8 The
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Selected abbreviations and acronyms
COX cyclo-oxygenase
IDO indoleamine 2,3-dioxygenase
IL interleukin
KYN kynurenine
KYNA kynurenic acid
MD major depression
QUIN quinolinic acid
TDO tryptophan 2,3-dioxygenase
TNF tumor necrosis factor
Components Innate Adaptive
Cellular Monocytes T- and B-cells
Makrophages
Granulocytes
Natural killer cells
γ/δ-cells
Humoral Complement, acute-phase protein,  Antibodies
mannose-binding lectin 
Table I. Components of the unspecific “innate” and the specific “adap-
tive” immune systems in humans. 
Type-1 Type-2
Cytokines IL-2 IL-4
IL-12 IL-13
IFN-γ [IL-10]
IL-18
(TNF-α)
Table II. Cytokines of the polarized immune response. IL, interleukin;
IFN, interferon; TNF, tumor necrosis factor.
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gle pathogen, may be related to the increased risk for
schizophrenia in the offspring.
9 Indeed, increased IL-8
levels of mothers during the second trimester were asso-
ciated with an increased risk for schizophrenia in the off-
spring.
7 A fivefold increased risk for developing psy-
choses later on was detected after infection of the
central nervous system (CNS) in early childhood.
7,10
These data were confirmed in recent studies.
11,12, 13
Signs of inflammation were found in schizophrenic
brains,
14 and the term “mild localized chronic encephali-
tis” to describe a slight but chronic inflammatory process
in schizophrenia was proposed.
15
An inflammatory model of MD is “sickness behavior,” the
reaction of the organism to infection and inflammation.
Sickness behavior is characterized by weakness, malaise,
listlessness, inability to concentrate, lethargy, decreased
interest in the surroundings, and reduced food intake—
all of which are depression-like symptoms. The sickness-
related psychopathological symptoms during infection
and inflammation are mediated by proinflammatory
cytokines such as IL-1, IL-6, TNF-α, and IFN-γ. The active
pathway of these cytokines from the peripheral immune
system to the brain is via afferent neurons and through
direct targeting of the amygdala and other brain regions
after diffusion at the circumventricular organs and
choroid plexus. Undoubtedly, there is a strong relation-
ship between the cytokine and the neurotransmitter sys-
tems, but the specific mechanisms underlying the hetero-
geneous disease MD are not yet fully understood. 
In humans, the involvement of cytokines in the regula-
tion of the behavioral symptoms of sickness behavior
has been studied by application of the bacterial endo-
toxin lipoploysaccharide (LPS) to human volunteers.
16
LPS, a potent activator of proinflammatory cytokines,
was found to induce mild fever, anorexia, anxiety,
depressed mood, and cognitive impairment. The levels
of anxiety, depression, and cognitive impairment were
found to be related to the levels of circulating
cytokines.
17
Mechanisms that may contribute to inflammation and
cause depressive states are:
￿ A direct influence of proinflammatory cytokines on
the serotonin and noradrenaline metabolism
￿ An imbalance of the type-1—type-2 immune response
leading to an increased tryptophan and serotonin
metabolism by activation of indoleamine 2,3-dioxyge-
nase (IDO) in the CNS, which is associated with:
-A decreased availability of tryptophan and serotonin
-A disturbance of the kynurenine metabolism with
an imbalance in favour of the production of the
NMDA receptor agonist quinolinic acid (QUIN)
-An imbalance in astrocyte and microglial activation
associated with increased production of QUIN.
Effects of antidepressants on the immune function sup-
port this view. The mechanisms and the therapeutic
implications will be discussed below.
Inflammation, caused by infection or by other mecha-
nisms, seems to play a role in schizophrenia and in MD.
Type-1 and type-2 immune responses in schizophrenia
A well established finding in schizophrenia is the
decreased in vitro production of IL-2 and IFN-γ,
18,19
reflecting a blunted production of type-1 cytokines.
Decreased levels of neopterin, a product of activated
monocytes/macrophages, also point to a blunted activa-
tion of the type-1 response.
20The decreased response of
lymphocytes after stimulation with specific antigens
reflects a reduced capacity for a type-1 immune response
in schizophrenia, as well.
21 intracellular adhesion mole-
cule (ICAM)-1 is a type-1 related protein and a cell-
adhesion molecule expressed on macrophages and lym-
phocytes. Decreased levels of the soluble (s) intercellular
adhesion molecule-1 (ICAM-1), as found in schizophre-
nia, also represent an underactivation of the type-1
immune system.
22 Decreased levels of the soluble TNF-
receptor p55—mostly decreased when TNF-α is
decreased—were observed, too.
23A blunted response of
the skin to different antigens in schizophrenia was
observed before the era of antipsychotics.
24This finding
could be replicated in unmedicated schizophrenic
patients using a skin test for the cellular immune
response.
25 However, there are some conflicting results
regarding increased levels of Th1 cytokines in schizo-
phrenia.
26 The latest meta-analysis showed dominant
proinflammatory changes in schizophrenia but not
involving Th2 cytokines.
27After including antipsychotic
medication effects into the analysis, only increases of IL-
1 receptor antagonist serum levels and of IL-6 serum lev-
els were found. Type-1 parameters, hypothesized to be
downregulated in schizophrenia, were not included in the
meta-analysis, because only a few studies have been per-
formed in unmedicated patients. 
Several reports described increased serum IL-6 levels in
schizophrenia.
28 IL-6 serum levels might be especially
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ease.
29 IL-6 is a product of activated monocytes, and some
authors refer to it as a marker of the type-2 immune
response. Moreover, several other signs of activation of
the type-2 immune response are described in schizo-
phrenia, including increased Th2 type of lymphocytes in
the blood,
30 increased production of immunoglobulinE
(IgE), and an increase in IL-10 serum levels.
31,32 In the
CSF, IL-10 levels were found to be related to the sever-
ity of the psychosis.
32
The key cytokine of the type-2 immune response is IL-
4. Increased levels of IL-4 in the CSF of juvenile schizo-
phrenic patients have been reported,
33 which indicates
that the increased type-2 response in schizophrenia is
not only a phenomenon of the peripheral immune
response.
However, the data show that the immune response in
schizophrenia can be confounded partly by factors spe-
cific to the disease such as its duration, chronicity, or
therapy response, and partly by other factors such as
antipsychotic medication, smoking, etc.
Increased proinflammatory type-1 cytokines in major
depression
Characteristics of the immune activation in MD include
increased numbers of circulating lymphocytes and
phagocytic cells, upregulated serum levels of indicators
of activated immune cells (neopterin, soluble IL-2 recep-
tors), and higher serum concentrations of positive acute
phase proteins (APPs), coupled with reduced levels of
negative APPs, as well as increased release of proin-
flammatory cytokines, such as IL-1, IL-2, TNF-α and IL-
6 through activated macrophages and IFN-γ through
activated T-cells.
32-39 Increased numbers of peripheral
mononuclear cells in MD have been described by dif-
ferent groups of researchers.
40
Neopterin is a sensitive marker of the cell-mediated
type-1 immunity. The main sources of neopterin are
monocytes/macrophages. In accordance with the find-
ings of increased monocytes/macrophages, an increased
secretion of neopterin has been described by several
groups of researchers.
41, 42
The increased plasma concentrations of the proinflam-
matory cytokines IL-1 and IL-6 observed in depressed
patients was found to correlate with the severity of
depression and with measures of the hypothalamus-pitu-
itary-adrenal (HPA)-axis hyperactivity.
43, 44 As genetics
plays a role in MD, the genetics of the immune system in
relation to MD has also been investigated. Particular
cytokine gene polymorphisms, eg, in genes coding for IL-
1 and TNF-α may confer a greater susceptibility to
develop MD, although studies are conflicting.
45, 46
The production of IL-2 and IFN-γ is the typical marker
of a type-1 immune response. In contrast to schizophre-
nia, IFN-γ is produced in greater amounts by lympho-
cytes of patients with MD than of healthy controls.
42, 45
Higher plasma levels of IFN-γ in depressed patients,
accompanied by lower plasma tryptophan availability
were described,
42 and the IFNγ/IL-4 ratio, a marker for
Th1/Th2 balance is also higher in depressed patients.
45
Data on IL-2 in MD are mainly restricted to the estima-
tion of its soluble receptor sIL-2R in the peripheral
blood. Increased sIL-2R levels reflect an increased pro-
duction of IL-2. The blood levels of sIL-2R were repeat-
edly found to be increased in MD patients.
39
Increased expression of ICAM-1 is observed in inflam-
matory processes, and promotes the influx of peripheral
immune cells through the blood-brain barrier.
47 By this
mechanism, macrophages and costimulatory lympho-
cytes can invade the central nervous system (CNS), fur-
ther increasing the proinflammatory immune response.
The plasma levels and CNS expression of ICAM-1 are
associated with depressive symptoms in patients treated
with IFN-γ. Increased sICAM-1 levels were observed in
patients with more depressive symptoms,
48 and increased
expression of ICAM-1 was found in the prefrontal cor-
tex of elderly depressed patients.
49 In late-life depression,
however, there are conflicting results.
50
Since different pathologies may underlie the syndrome
of depression, different immunological states might be
involved. Indeed, different types of MD were observed
to exhibit different immune profiles: the subgroup of
melancholic depressed patients showed a decreased
type-1 activation—as observed in schizophrenic
patients
40—while the nonmelancholic depressed patients
showed signs of inflammation such as increased mono-
cyte count and increased levels of α2-macroglobulin.
40
Suicidality, observed in a very high proportion of
depressed patients, seems to be an example of the
immune activation pattern in depression, since clinical
studies have observed higher levels of type-1 cytokines
in suicidal patients. In a small study, distinct associations
between suicidality and type-1 immune response and a
predominance of type-2 immune parameters in nonsui-
cidal patients were observed.
51An epidemiological study
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suicidality.
52 Increased levels of serum sIL-2R have been
described in medication-free suicide attempters, irre-
spective of the psychiatric diagnosis,
53 and treatment with
high-dose IL-2 has been associated with suicide in a case
report.
54
These data show that possible different immune states
within the category of MD need to be better differentiated.
The predominant proinflammatory, type-1 dominated
immune state described in MD may be a kind of model
state state restricted to a majority of patients suffering from
MD. Therefore, these and other methodological concerns
have to be considered carefully in future studies.
Therapeutic mechanisms and the type-1/
type-2 imbalance in 
schizophrenia and depression
Schizophrenia: antipsychotic drugs correct the 
type-1/type-2 imbalance
In-vitro studies show that the blunted IFN-γ production
becomes normalized after therapy with neuroleptics.
18
An increase of “memory cells” (CD4
+CD45RO
+) cells—
one of the main sources of IFN-γ production—during
antipsychotic therapy with neuroleptics was observed by
different groups.
55Additionally, an increase of sIL-2R—
the increase reflects an increase of activated, IL-2 bear-
ing T-cells—during antipsychotic treatment was
described.
56 The reduced sICAM-1 levels show a signif-
icant increase during short-term antipsychotic therapy,
22
and the ICAM-1 ligand leukocyte function antigen-1
(LFA-1) shows a significantly increased expression dur-
ing antipsychotic therapy.
57 The increase of TNF-α and
TNF-α  receptors during therapy with clozapin was
observed repeatedly.
58 Moreover, the blunted reaction to
vaccination with Salmonella typhii was not observed in
patients medicated with antipsychotics.
59An elevation of
IL-18 serum levels was described in medicated schizo-
phrenics.
60 Since IL-18 plays a pivotal role in the type-1
immune response, this finding is consistent with other
descriptions of type-1 activation during antipsychotic
treatment. 
Regarding the type-2 response, several studies point out
that antipsychotic therapy is accompanied by a func-
tional decrease of the IL-6 system.
19,61These findings pro-
vide further evidence that antipsychotics have a “bal-
ancing” effect on cytokines.
Therapeutic techniques in depression are associated
with downregulation of the proinflammatory immune
response
Antidepressant pharmacotherapy
A modulatory, predominantly inhibitory effect of selec-
tive serotonin reuptake inhibitors (SSRIs) on activation
of proinflammatory immune parameters was demon-
strated in animal experiments.
62, 63
Several antidepressants seem to be able to induce a shift
from type 1 to type 2, in other words from a proinflam-
matory to an anti-inflammatory immune response, since
the ability of three antidepressants (sertraline,
clomipramine, and trazodone) to greatly reduce the IFN-
γ/IL-10 ratio was shown in vitro. These drugs reduced the
IFN-γ production significantly, while sertraline and
clomipramine additionally raised the IL-10 production.
61
Regarding other in-vitro studies, a significantly reduced
production of IFN-γ, IL-2, and sIL-2R was found after
antidepressant treatment compared with pretreatment
values.
63 A downregulation of the IL-6 production was
observed during amitriptyline treatment; in treatment
responders, the TNF-α production decreased to normal.
66
There are also studies, however, showing no effect of
antidepressants to the in-vitro stimulation of cytokines
(overview, ref 67) but methodological issues have to be
taken into account. There is significant evidence suggest-
ing that antidepressants of different classes induce down-
regulation of the type 1 cytokine production in vitro,
67
including noradrenaline reuptake inhibitors
68 and the
“dual” serotonin and noradrenalin reuptake inhibitors.
69
Several researchers have observed a reduction of IL-6
during treatment with the serotonin reuptake inhibitor
fluoxetine.
70A decrease of IL-6 serum levels during ther-
apy with different antidepressants has been observed by
other researchers.
71 The shift of imbalanced IFNγ/IL-4
towards normal after 6 weeks' antidepressant treatment
has also been reported.
41 On the other hand, other
groups did not find any effect of some antidepressants
on serum levels of different cytokines.
61, 72
Since IL-6 stimulates PGE2 and antidepressants inhibit IL-
6 production, an inhibiting action of antidepressants on
PGE2 would be expected, too.
73 Over 30 years ago it was
suggested that antidepressants inhibit PGE2.
74A recent in-
vitro study showed that both tricyclic antidepressants and
selective serotonin inhibitors attenuated cytokine-induced
PGE2 and nitric oxide production by inflammatory cells.
75
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therapy and sleep deprivation
Electroconvulsive therapy (ECT) was found to down-
regulate increased levels of the proinflammatory
cytokine TNF-α in patients with MD.
76
An immune analysis during sleep showed an increase in
the type-1 monocyte derived cytokines TNF-α and IL-
12 and a decrease of the type-2 IL-10 producing mono-
cytes.
77 In contrary, continuous wakefulness blocked the
increase of type-1 and decrease of type-2 cytokines (T.
Lange and S. Dimitrov, personal communication). Thus,
sleep deprivation may exert therapeutic effects through
a low suppression of type-1 cytokines.
Antidepressant pharmacotherapy, but also other anti-
depressant therapeutic agents or techniques, have a
downregulating effect on proinflammatory cytokines.
Divergent effects of type-1 type-2 immune
activation are associated with different
effects on the kynurenine metabolism in
schizophrenia and depression
Schizophrenia
The only known naturally occurring NMDA receptor
antagonist in the human CNS is kynurenic acid
(KYNA). KYNA is one of the several neuroactive inter-
mediate products of the kynurenine pathway (Figure 1).
Kynurenine (KYN) is the primary major degradation
product of tryptophan (TRP). While the excitatory KYN
metabolites 3-hydroxykynurenine (3HK) and QUIN are
synthesized from KYN in the process toward NAD for-
mation, KYNA is formed in a dead-end side arm of the
pathway.
78
KYNA acts both as a blocker of the glycine coagonis-
tic site of the NMDA receptor and as a noncompetitive
inhibitor of the α7 nicotinic acetylcholine receptor.
79
The production of KYN metabolites is partly regulated
by IDO and tryptophan 2,3-dioxygenase (TDO). Both
enzymes catalyze the first step in the pathway, the degra-
dation from tryptophan to kynurenine. Type-1 cytokines,
such as IFN-γ and IL-2, stimulate the activity of IDO.
80
There is a mutual inhibitory effect of TDO and IDO: a
decrease in TDO activity occurs concomitantly with
IDO induction, resulting in a coordinate shift in the site
(and cell types) of tryptophan degradation.
81While it has
been known for a long time that IDO is expressed in dif-
ferent types of CNS cells, TDO was thought for many
years to be restricted to liver tissue. It is known today,
however, that TDO is also expressed in CNS cells, prob-
ably restricted to astrocytes.
82
The type-2 or Th-2 shift in schizophrenia may result in a
downregulation of IDO through the inhibiting effect of
Th2 cytokines. TDO, on the other hand, was shown to be
overexpressed in postmortem brains of schizophrenic
patients.
82The type-1/type-2 imbalance with type-2 shift
is therefore associated with overexpression of TDO.
The type 1/type 2 imbalance is associated with the acti-
vation of astrocytes and an imbalance in the activation
of astrocytes/microglial cells.
83 The functional excess of
astrocytes may lead to a further accumulation of KYNA.
Indeed, a study referring to the expression of IDO and
TDO in schizophrenia showed exactly the expected
results. An increased expression of TDO compared with
IDO was observed in schizophrenic patients and the
increased TDO expression was found, as expected, in
astrocytes, not in microglial cells.
82
However, it is necessary to note that the above proposed
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Figure 1. Neuroimmune interactions of kynurenine intermediates.
Metabolism of tryptophan via the kynurenine pathway leads
to several neuroactive intermediates: kynurenic acid (synthe-
sised by kynurenine aminotransferase, KAT) has neuroprotec-
tive properties through antagonism at the N-methyl-D-
aspartate (NMDA) receptor. Quinolinic acid (QUIN), in contrast,
is an NMDA receptor agonist. Both 3-hydroxykynurenine (3-
OH-kynurenine) and QUIN can induce neurodegeneration and
apoptosis through induction of excitotoxicity and generation
of neurotoxic radicals, respectively. Activity of the key enzyme
of the kynurenine pathway, indoleamine 2,3-dioxygenase
(IDO), and of the 3-OH-kynurenine forming enzyme kynure-
nine monoxygenase (KMO) is induced by proinflammatory
cytokines like interferon-γ (IFN-γ) and inhibited by anti-inflam-
matory cytokines like interleukin-4 (IL-4). Serotonin is normally
degraded to 5-hydroxyindoleacetic acid (5-HIAA), but the
indole ring of serotonin can also be cleaved by IDO. (blue
arrows = activation; red arrows = inhibition).
Tryptophan
Kynurenine Kynurenine
acid
IFN-γ
IFN-γ
Serotonin
IL-4
IL-4
3-OH-Kynurenine
IDO
IDO
KAT
KMO
Quinolinic acid
Neuroprotection
Neurotoxic
radicals
= NMDA-R agonist
= NMDA-R
antagonist
Neurodegeneration +
apoptosis
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ophrenic patients with Th2 dominant immune response.
In those schizophrenics with Th1 dominant immune
response, the kynurenine pathway changes would be
more similar to those changes in MD.
84, 85
Major depression
Two directing enzymes of the kynurenine metabolism,
IDO and kynurenine monoxygenase (KMO), are
induced by the type-1 cytokine IFN-γ. The activity of
IDO is an important regulatory component in the con-
trol of lymphocyte proliferation, the activation of the
type-1 immune response, and the regulation of the tryp-
tophan metabolism.
85 It induces a halt in the lymphocyte
cell cycle due to the catabolism of tryptophan.
87 In con-
trast to the type-1 cytokines, the type-2 cytokines IL-4
and IL-10 inhibit the IFN-γ-induced IDO-mediated tryp-
tophan catabolism.
87 IDO is located in several cell types,
including monocytes and microglial cells.
88 An IFN-γ-
induced, IDO-mediated decrease of CNS tryptophan
availability may lead to a serotonergic deficiency in the
CNS, since tryptophan availability is the limiting step in
serotonin synthesis. Other proinflammatory molecules
such as PGE2 or TNF-α, however, induce synergistically
with IFN-γ the increase of IDO activity.
89Therefore, not
only IFN-γ and type-1 cytokines, but also other proin-
flammatory molecules induce IDO activity. Since
increased levels of PGE2 and TNF-α were described in
MD, other proinflammatory molecules also contribute
to IDO activation and tryptophan consumption, (eg, ref
39). An imbalance between the NMDA antagonist
action by KYNA and the NMDA agonist action by
QUIN has been proposed to be involved in the patho-
physiology of MD
90; a recent study demonstrated this
imbalance in patients with MD.
3 Accordingly, since the
activity of the enzyme kynurenine 3 mono-oxygenase
(KMO), directing the production of QUIN, is inhibited
by type-2 cytokines but activated by proinflammatory
type-1 cytokines,
91 an increased production of QUIN in
depressive states would be expected. The role of QUIN
in depression is discussed in more detail below.
One of the more consistent findings is that patients with
low 5-hydroxyindoleacetic acid (5-HIAA), the metabolite
of serotonin, in CSF are prone to commit suicide.
92, 93This
gives further indirect evidence for a possible link between
the type-1 cytokine IFN-γ and the IDO-related reduction
of serotonin availability in the CNS of suicidal patients. 
A study in patients suffering from hepatitis C showed
that immunotherapy with IFN-γ was followed by an
increase of depressive symptoms and serum kynurenine
concentrations on the one hand, and a decrease in serum
concentrations of tryptophan and serotonin on the other
hand.
94 The kynurenine/tryptophan ratio, which reflects
the activity of IDO, increased. Changes in depressive
symptoms were significantly positively correlated with
kynurenine and negatively correlated with serotonin
concentrations.
94This study and others
95 clearly show that
the IDO activity is increased by IFN, leading to an
increased kynurenine production and a depletion of
tryptophan and serotonin. The further metabolism of
kynurenine, however, seems to play an additional crucial
role for the psychopathological states.
In addition to the effects of the proinflammatory
immune response on the serotonin metabolism, other
neurotransmitter systems, in particular the cate-
cholaminergic system, are involved in depression, too.
Although the relationship of immune activation and
changes in catecholaminergic neurotransmission has not
been well studied, an increase in monoamino-oxidase
(MAO) activity, which leads to decreased noradrenergic
neurotransmission, might be an indirect effect of the
increased production of kynurenine and QUIN.
45
The proinflammatory immune state in MD leads on the
one hand to a lack of serotonin and on the other hand to
an overproduction of the neurotoxic and depressiogenic
metabolite QUIN by induction of the directing enzymes
of the kynurenine metabolism. Two depressiogenic com-
ponents result from the IDO activation.
Astrocytes, microglia, and 
type-1/type-2 response
The cellular sources for the immune response in the CNS
are astrocytes and microglia cells. Microglial cells, deriv-
ing from peripheral macrophages, secrete preferantially
type-1 cytokines such as IL-12, while astrocytes inhibit
the production of IL-12 and ICAM-1 and secrete the
type-2 cytokine IL-10.
96 Therefore, the type-1/type-2
imbalance in the CNS seems to be represented by the
imbalance in the activation of microglial cells and astro-
cytes, although it has to be taken into consideration that
the production of cytokines by astrocytes and microglial
cells depends on activation conditions. The hypothesis of
an overactivation of astrocytes in schizophrenia is sup-
ported by the finding of increased CSF levels of S100B—
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medication state of the schizophrenic patients.
97 Microglia
activation was found in a small percentage of schizo-
phrenics and is speculated to be a medication effect.
98A
type-1 immune activation as an effect of antipsychotic
treatment has repeatedly been observed.
Since the type-1 activation predominates in the response
of the peripheral immune system in depression, a domi-
nance of microglial activation compared with astrocyte
activation should be observed in depression. Glial reduc-
tions were consistently found in brain circuits known to be
involved in mood disorders, such as in the limbic and pre-
frontal cortex.
99, 100Although several authors did not dif-
ferentiate between microglial and astrocytic loss, this dif-
ference is crucial due to the different effects of the
type-1/type-2 immune response. Recent studies, however,
show that astrocytes are diminished in patients suffering
from depression,
101 although the data are not entirely con-
sistent.
102A loss of astrocytes was in particular observed in
younger depressed patients: the lack of glial fibrillary acid
protein (GFAP)-immunoreactive astrocytes reflects a low-
ered activity of responsiveness in those cells.
101A loss of
astrocytes was found in many cortical layers and in differ-
ent sections of the dorsolateral prefrontal cortex in depres-
sion.
103A reduction of astrocytes has also been observed in
the dentate gyrus of an animal model of IFN-α induced
depression (Myint et al, personal communication).
Moreover, a loss of astrocytes is associated with an
impaired reuptake of glutamate from the extracellular
space into astrocytes by high affinity glutamate trans-
porters.
104 Impaired glutamate reuptake from the synap-
tic cleft by astroglia prolongs synaptic activation by glu-
tamate.
105 Accordingly, increased glutamatergic activity
has been observed in patients with depression.
106
Neuroprotective and neurotoxic metabolites of the
tryptophan-kynurenine metabolism in psychiatric 
disorders
In contrast to microglial cells which produce QUIN,
astrocytes play a key role in the production of KYNA in
the CNS. Astrocytes are the main source of KYNA.
107
The cellular localization of the kynurenine metabolism
is primarily in macrophages and microglial cells, but also
in astrocytes.
108 KMO, a critical enzyme in the kynure-
nine metabolism, is absent in human astrocytes, how-
ever.
109 Accordingly, it has been pointed out that astro-
cytes cannot produce the product 3-hydroxykynurenine
(3-HK), but they are able to produce large amounts of
early kynurenine metabolites, such as KYN and
KYNA.
109 This supports the observation that inhibition
of KMO leads to an increase in the KYNA production
in the CNS.
110 The complete metabolism of kynurenine
to QUIN is observed mainly in microglial cells, only a
small amount of QUIN is produced in astrocytes via a
side-arm of the kynurenine metabolism. Therefore, due
to the lack of kynurenine-hydroxylase (KYN-OHse), in
case of high tryptophan breakdown to KYN, KYNA
may accumulate in astrocytes. 
A second key player in the metabolization of 3-HK are
monocytic cells infiltrating the CNS. They help astrocytes
in the further metabolism to QUIN.
109 However, the low
levels of sICAM-1 (ICAM-1 is the molecule that mainly
mediates the penetration of monocytes and lymphocytes
into the CNS) in the serum and in the CSF of nonmed-
icated schizophrenic patients,
22 and the increase of adhe-
sion molecules during antipsychotic therapy indicate
that the penetration of monocytes may be reduced in
nonmedicated schizophrenic patients.
57
Quinolinic acid as a depressiogenic and neurotoxic 
substance
Apart from certain liver cells, only macrophage-derived
cells are able to convert tryptophan into quinolinic aci-
dolonic acid.
111 Interestingly, in a model of infection, the
highest concentrations of QUIN are found in the gray
and white matter of the cortex, not in subcortical areas.
This finding points out that high levels of QUIN there-
fore may be associated with cortical dysfunction.
112
The strong association between cortical QUIN concen-
trations and local IDO activity supports the view that
the induction of IDO is an important event in initiating
the increase of QUIN production.
113 In the CNS, invaded
macrophages and microglial cells are able to produce
QUIN.
111 During a local inflammatory CNS process, the
QUIN production in the CNS might increase without
changes of the peripheral blood levels of QUIN. The
local QUIN production correlates with the level of β2
microglobulin, an inflammatory marker. Local CNS con-
centrations of QUIN are able to exceed the blood levels
by far.
112 Peripheral immune stimulation, however, under
certain conditions also leads to increased CNS concen-
tration of QUIN.
111
A recent study showed that depressive symptoms are
related to an high ratio of KYN/KYNA in depression.
114
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KYN may be preferentially metabolized to QUIN, while
the KYNA pathway is neglected. 
The increase of QUIN was observed to be associated
with several prominent features of depression: decrease
in reaction time
115 and cognitive deficits, in particular dif-
ficulties in learning.
112 In an animal model, an increase of
QUIN and 3-hydroxykynurenine was associated with
anxiety.
116
QUIN was shown to cause an over-release of glutamate
in the striatum and in the cortex, presumably by presy-
naptic mechanisms.
117The QUIN pathway of the kynure-
nine metabolism—directed by proinflammatory
cytokines—might be the key mechanism involved in the
increased glutamatergic neurotransmission in MD,
106
while it is unclear whether QUIN itself has depressio-
genic properties. Thus, an excess of QUIN might be asso-
ciated with excess glutamatergic activation.
COX-2 inhibition as a therapeutic approach in 
schizophrenia and depression
COX inhibition provokes differential effects on kynure-
nine metabolism: while COX-1 inhibition increases the
levels of KYNA, COX-2 inhibition decreases them.
118
Therefore, psychotic symptoms and cognitive dysfunc-
tions, observed during therapy with COX-1 inhibitors,
were assigned to the COX-1 mediated increase of KYNA.
The reduction of KYNA levels, by a prostaglandin-medi-
ated mechanism, might be an additional mechanism to the
above-described immunological mechanism for thera-
peutic effects of selective COX-2 inhibitors in schizo-
phrenia.
118
Indeed, in a prospective, randomized, double-blind study
of therapy with the COX-2 inhibitor celecoxib added on
to risperidone in acute exacerbation of schizophrenia, a
therapeutic effect of celecoxib was observed.
119
Immunologically, an increase of the type-1 immune
response was found in the celecoxib treatment group.
120
The finding of a clinical advantage of COX-2 inhibition,
however, could not be replicated in a second study.
Further analysis of the data revealed that the outcome
depends on the duration of the disease.
121 This observa-
tion is in accordance with results from animal studies
showing that the effects of COX-2 inhibition on
cytokines, hormones, and particularly on behavioral
symptoms are dependent on the duration of the pre-
ceding changes and the time point of application of the
COX-2 inhibitor.
122 In subsequent clinical studies fol-
lowing a similar randomized double-blind placebo-con-
trolled add-on design of 400 mg celecoxib to risperidone
(in one study risperidone or olanzapine) in partly dif-
ferent patient populations, similar positive results of
cyclo-oxygenase inhibition were able to be obtained: in
a Chinese population of first-manifestation schizo-
phrenics,
123 and in an Iranian sample of chronic schizo-
phrenics.
124 In continuously ill schizophrenics, however,
no advantage of celecoxib could be found.
125 In schizo-
phrenia, COX-2 inhibition showed beneficial effects
preferentially in early stages of the disease, the data
regarding chronic schizophrenia are controversial, pos-
sibly in part due to methodological concerns. The data
are still preliminary and further research has to be per-
formed, eg, with other COX-2 inhibitors.
COX-2 inhibition as a possible anti-inflammatory 
therapeutic approach in depression
Due to the increase of proinflammatory cytokines and
PGE2 in depressed patients, anti-inflammatory treatment
would be expected to show antidepressant effects also in
depressed patients. In particular, COX-2 inhibitors seem
to show advantageous results: animal studies show that
COX-2 inhibition can lower the increase of the proin-
flammatory cytokines IL-1β, TNF-α, and of PGE2, but it
can also prevent clinical symptoms such as anxiety and
cognitive decline, which are associated with this increase
of proinflammatory cytokines.
122 Moreover, treatment
with the COX-2 inhibitor celecoxib—but not with a
COX-1 inhibitor—prevented the dysregulation of the
HPA-axis, in particular the increase of cortisol, one of the
biological key features associated with depression.
122, 126
This effect can be expected because PGE2 stimulates the
HPA axis in the CNS,
127 and PGE2 is inhibited by COX-
2 inhibition. Moreover, the functional effects of IL-1 in
the CNS—sickness behavior being one of these effects—
were also shown to be antagonized by treatment with a
selective COX-2 inhibitor.
128
Additionally, COX-2 inhibitors influence the CNS sero-
tonergic system. In a rat model, treatment with rofecoxib
was followed by an increase of serotonin in the frontal
and the temporoparietal cortex.
129A possible mechanism
of the antidepressant action of COX-2 inhibitors is the
inhibition of the release of IL-1 and IL-6. Moreover,
COX-2 inhibitors also protect the CNS from effects of
QUIN, ie, from neurotoxicity.
130 In the depression model
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in the hypothalamus and a change in behavior have been
observed after chronic celecoxib treatment.
131 In another
animal model of depression, however, the mixed COX-
1/COX-2 inhibitor acetylsalicylic acid showed an addi-
tional antidepressant effect by accelerating the antide-
pressant effect of fluoxetine.
132
Moreover, we were able to demonstrate a significant
therapeutic effect of the COX-2 inhibitor on depressive
symptoms in a randomized, double-blind pilot add-on
study using the selective COX-2 inhibitor celecoxib in
MD.
133 Also in a clinical study, the mixed COX-1/COX-
2 inhibitor acetylsalicylic acid accelerated the antide-
pressant effect of fluoxetine and increased the response
rate in depressed nonresponders to monotherapy with
fluoxetine in a open-label pilot study.
134 Currently, a large
study with the COX-2 inhibitor cimicoxib is ongoing. For
ethical reasons, clinical trials so far have been performed
in an add-on design; no monotherapy with a COX-2
inhibitor was studied.
Conclusion
A large number of findings point out that inflammation
plays a pivotal role in the pathogenesis of major psychi-
atric disorders, in particular in MD and in schizophrenia.
The differential influence of cytokines and proinflam-
matory mediators, which are altered in schizophrenia and
MD, on the enzyme IDO and the tryptophan/kynurenine
metabolism result in alterations of the serotonergic, glu-
tamatergic, and dopaminergic neurotransmissions; these
alterations are typically found in schizophrenia and MD.
The tryptophan/kynurenine metabolism, however, gen-
erates neurotoxic and neuroprotective metabolites, an
imbalance in this metabolism contributes to the produc-
tion of either the neurotoxic metabolite QUIN or the
neuroprotective metabolite KYNA, both exhibiting dif-
ferent effects on the glutamatergic neurotransmission.
Additionally, a direct influence of cytokines on neuro-
transmitters has been noted. Moreover, cytokines can
also act in a neurotoxic and neuroprotective manner.
Anti-inflammatory drugs, however, are candidates for
antidepressants and antipsychotics, which might be more
related to the pathophysiology of these disorders com-
pared with the neurotransmitter disturbances. The neu-
rotransmitter disturbances might be a final common
pathway of different pathological pathways in schizo-
phrenia and depression, the immunological pathway
might be true for a subgroup of patients suffering from
these disoders. COX-2 inhibitors—most studies have
been performed with celecoxib—have been shown in in-
vitro experiments, animal studies, and clinical trials by
several groups of researchers to exhibit antidepressant
and antipsychotic properties. Other anti-inflammatory
therapeutic approaches will be of interest in the future,
and possibly support the hypothesis that inflammation is
an important pathogenetic factor in depression and schiz-
ophrenia. ❏
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El impacto de la falta de regulación 
neuroinmune sobre la neuroprotección y la
neurotoxicidad en los trastornos 
psiquiátricos: su relación con tratamientos
farmacológicos 
Se ha postulado una patogénesis inflamatoria para
la esquizofrenia y la depresión mayor (DM). En la
esquizofrenia y la depresión, patrones opuestos de
respuesta inmune tipo 1 versus tipo 2 parecen estar
asociados con diferencias en la activación de la
enzima indolamina 2,3 dioxigenasa y en el meta-
bolismo triptófano-kinurenina, lo que lleva a un
aumento de la producción de ácido kinurénico en
la esquizofrenia y disminución de la producción de
este ácido en la depresión. Estas diferencias están
asociadas con un desequilibrio en la neurotransmi-
sión glutamatérgica, el cual puede contribuir a una
excesiva acción agonista del N-metil-D-aspartato
(NMDA) en la depresión y otra antagonista del
NMDA en la esquizofrenia. Respecto a la función
neuroprotectora del ácido kinurénico y a los efec-
tos neurotóxicos del ácido quinolínico (QUIN), los
diferentes patrones de activación inmune también
pueden llevar a un desequilibrio entre los efectos
neuroprotectores y neurotóxicos del metabolismo
triptófano/kinurenina. La activación diferencial de
las células de la microglía y los astrocitos puede ser
un mecanismo adicional que contribuya a este dese-
quilibrio. El desequilibrio inmunológico se traduce
en un estado inflamatorio combinado con un
aumento de la producción de prostaglandina E2 y
aumento de la expresión de ciclo-oxigenasa-2 (COX-
2). Sin embargo, los efectos inmunológicos de
muchos de los antipsicóticos y antidepresivos exis-
tentes corrigen parcialmente el desequilibrio
inmune y el exceso de producción del neurotóxico
QUIN. Los inhibidores de la COX-2 se han evaluado
en modelos animales de depresión y en ensayos clí-
nicos preliminares, y orientan a efectos favorables
en la esquizofrenia y en la DM. 
Impact d’une dysrégulation neuro-immune
sur la neuroprotection et la neurotoxicité
dans les troubles psychiatriques- relation
avec le traitement médicamenteux
L’hypothèse d’une pathogenèse inflammatoire a
été avancée pour la schizophrénie et la dépression
majeure (DM). Dans la schizophrénie et la dépres-
sion, l’opposition des réponses immunes de type 1
vs type 2 semble être associée à des différences
dans l’activation de l’enzyme indoleamine 2,3-
dioxygénase et dans le métabolisme tryptophane-
kynurénine, la production d’acide kynurétique
étant augmentée dans la schizophrénie et dimi-
nuée dans la dépression. Ces différences sont asso-
ciées à un déséquilibre de la neurotransmission glu-
tamatergique qui peut entraîner une action
agoniste excessive du NMDA (N-méthyl-D-
aspartate) dans la dépression et à une action anta-
goniste dans la schizophrénie. En ce qui concerne
la fonction neuroprotectrice de l’acide kynurétique
et les effets neurotoxiques de l’acide quinolinique
(QUIN), différents schémas d’activation immunitaire
peuvent aussi conduire à un déséquilibre entre les
effets neuroprotecteurs et neurotoxiques du méta-
bolisme tryptophane/kynurénine, auquel peut
contribuer l’activation différentielle des cellules de
la microglie et des astrocytes. Le déséquilibre immu-
nologique provoque un état inflammatoire associé
à une production augmentée de prostaglandine E2
et à une expression augmentée de la COX-2 (cyclo-
oxygénase-2). Les effets immunologiques de nom-
breux antipsychotiques et antidépresseurs existants
corrigent cependant en partie ce déséquilibre
immunitaire et l’excès de production du neuro-
toxique QUIN. Les inhibiteurs de la COX-2 ont été
testés dans des modèles animaux de dépression et
dans des études cliniques préliminaires, montrant
des effets favorables dans la schizophrénie et la
dépression.
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